Please select the option that best describes you:
When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?
Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ever start ADT without metastatic disease?
Answer from: Medical Oncologist at Community Practice
There is no right or wrong answer here. The Johns Hopkins approach is to always recommend a clinical trial for the nonmetastatic BCR population. In the absence of a trial, our group does not believe that early ADT is justified in men with PSADT >9 months, where metastasis-free survival approaches...
Sign in or Register to read more